Taken together, our findings provide valuable insight into the underlying biology behind the actions of SPR965 as a dual inhibitor of the AKT/mTOR pathway, and highlight the potential promise of this agent in the treatment of highly lethal ovarian cancer. The gene discussed is AKT1; the disease is ovarian cancer.